Zoetis Inc - Class A chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 17.23
Dividend & Yield1.50$ (0.90%)
Beta 0.74
Market capitalization 79.04B
Operating cash flow 1.91B
ESG Scores 18.5

Company description

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides testing and analysis of blood, urine, and other animal samples and related products and services, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Sector: Healthcare - Industry: Drug Manufacturers—Specialty & Generic

Financial Ratios
Quick Ratio2.79
Working Capital0.4
Return On Equity0.45
Debt To Equity1.45
Fixed Asset Ratio0.12
Fixed Interest Cover12.55

Financial data

Financial Statements

Cashflow Statement 2019-12-31 2020-12-31 2021-12-31 2022-12-31
Change To Liabilities -10M 147M -17M -29M
Total Cashflows From Investing Activities -504M -572M -458M -883M
Net Borrowings -9M 744M -604M 1.35B
Total Cash From Financing Activities -951M 123M -1.86B -904M
Change To Operating Activities 32M 40M 195M -47M
Issuance Of Stock 7M 20M
Net Income 1.5B 1.64B 2.04B 2.11B
Change In Cash 332M 1.67B -119M 96M
Effect Of Exchange Rate -8M -7M -12M -29M
Total Cash From Operating Activities 1.79B 2.13B 2.21B 1.91B
Depreciation 385M 395M 396M 396M
Change To Account Receivables -69M 74M -155M -137M
Other Cashflows From Financing Activities -9M -11M -6M -11M
Change To Netincome 34M 132M 71M 32M
Capital Expenditures -460M -453M -477M -586M

Income Statement 2019-12-31 2020-12-31 2021-12-31 2022-12-31
Research Development 457M 463M 508M 539M
Income Before Tax 1.8B 2B 2.49B 2.66B
Net Income 1.5B 1.64B 2.04B 2.11B
Selling General Administrative 1.64B 1.71B 2B 2.01B
Gross Profit 4.34B 4.64B 5.48B 5.63B
Ebit 2.1B 2.3B 2.81B 2.94B
Operating Income 2.1B 2.3B 2.81B 2.94B
Interest Expense -223M -231M -224M -221M
Income Tax Expense 301M 360M 454M 545M
Total Revenue 6.26B 6.67B 7.78B 8.08B
Cost Of Revenue 1.92B 2.04B 2.29B 2.45B
Total Other Income ExpenseNet -296M -305M -323M -280M
Net Income From Continuing Ops 1.5B 1.64B 2.03B 2.11B
Net Income Applicable To Common Shares 1.5B 1.64B 2.04B 2.11B

Balance Sheet Statement 2019-12-31 2020-12-31 2021-12-31 2022-12-31
Total Liabilities 8.84B 9.84B 9.36B 10.52B
Total Stockholder Equity 2.71B 3.77B 4.54B 4.41B
Other Current Liabilities 171M 203M 232M 390M
Total Assets 11.54B 13.61B 13.9B 14.93B
Common Stock 5M 5M 5M 5M
Other Current Assets 314M 364M 389M 365M
Retained Earnings 4.43B 5.66B 7.19B 8.67B
Treasury Stock -2.77B -2.96B -3.72B -5.36B
Cash 1.93B 3.6B 3.48B 3.58B
Total Current Liabilities 1.81B 2.17B 1.8B 3.17B
Other Stockholder Equity -726M -730M -764M -817M
Property, Plant, and Equipment 2.13B 2.39B 2.6B 2.97B
Total Current Assets 4.75B 6.61B 6.93B 7.51B
Net Tangible Assets -1.77B -635M 387M 279M
Net Receivables 1.09B 1.01B 1.13B 1.22B
Accounts Payable 301M 457M 436M 405M


Insider Transactions

Here are the insider transactions of stock shares related to Zoetis Inc - Class A:

Filer Name Transaction Text Ownership Date Filer Relation Shares
LAGANO ROXANNESale at price 175.00 per share.D2023-02-14Officer13.01k
LAGANO ROXANNEConversion of Exercise of derivative security at price 73.24 - 87.51 per share.D2023-02-14Officer13.01k
PARENT LOUISE MD2023-02-10Director1.63k
BISARO PAUL M.D2023-02-10Director1.63k
REED WILLIE MD2023-02-10Director1.63k
MCCALLISTER MICHAEL BD2023-02-10Director1.63k
RHODES LINDAD2023-02-10Director1.63k
NORDEN GREGORYD2023-02-10Director1.63k
PECK KRISTIN CConversion of Exercise of derivative security at price 158.33 per share.D2023-02-10Chief Executive Officer13.41k
CHEN HEIDI CD2023-02-10Officer5.14k
LAGANO ROXANNEConversion of Exercise of derivative security at price 158.33 per share.D2023-02-10Officer1.86k
MAMILLI WAFAAD2023-02-10Officer5.82k
POLZER ROBERT JD2023-02-10Officer631
DRISCOLL RIMMAD2023-02-10Officer670
BRANNAN JAMIED2023-02-10Officer391
POLZER ROBERT JSale at price 171.77 per share.D2022-08-05Officer1.12k
POLZER ROBERT JD2022-08-05Officer1.72k
LAGANO ROXANNESale at price 180.26 per share.D2022-07-22Officer2.17k
LAGANO ROXANNEConversion of Exercise of derivative security at price 73.24 - 87.51 per share.D2022-07-22Officer2.17k
PECK KRISTIN CSale at price 180.00 per share.D2022-07-21Chief Executive Officer9.69k
PECK KRISTIN CConversion of Exercise of derivative security at price 30.89 - 41.83 per share.D2022-07-21Chief Executive Officer9.69k
PECK KRISTIN CSale at price 180.00 per share.D2022-07-07Chief Executive Officer311
PECK KRISTIN CD2022-07-07Chief Executive Officer311
LAGANO ROXANNESale at price 175.00 per share.D2022-06-27Officer4.33k
LAGANO ROXANNEConversion of Exercise of derivative security at price 73.24 - 87.51 per share.D2022-06-27Officer4.33k
REED WILLIE MSale at price 162.31 per share.D2022-06-10Director1.85k
LAGANO ROXANNESale at price 178.96 per share.D2022-04-26Officer2.17k
LAGANO ROXANNEConversion of Exercise of derivative security at price 73.24 - 87.51 per share.D2022-04-26Officer2.17k
TRAWICKI ROMANConversion of Exercise of derivative security at price 191.92 per share.D2022-03-16Officer6k
PECK KRISTIN CD2022-02-25Chief Executive Officer10k
DAVID GLENN CSale at price 188.95 - 190.70 per share.D2022-02-23Officer32.39k
DAVID GLENN CConversion of Exercise of derivative security at price 46.09 - 87.51 per share.D2022-02-23Officer32.39k
LAGANO ROXANNESale at price 196.54 per share.D2022-02-15Officer2.06k
PARENT LOUISE MD2022-02-11Director2.67k
REED WILLIE MConversion of Exercise of derivative security at price 198.87 per share.D2022-02-11Director2.67k
MCCALLISTER MICHAEL BConversion of Exercise of derivative security at price 198.87 per share.D2022-02-11Director2.67k
SCULLY ROBERT WConversion of Exercise of derivative security at price 198.87 per share.D2022-02-11Director2.67k
D AMELIO FRANK AConversion of Exercise of derivative security at price 198.87 per share.D2022-02-11Director2.67k
RHODES LINDAD2022-02-11Director2.67k
KHOSLA SANJAYConversion of Exercise of derivative security at price 198.87 per share.D2022-02-11Director2.67k
NORDEN GREGORYD2022-02-11Director2.67k
PECK KRISTIN CD2022-02-11Chief Executive Officer23.27k
CHEN HEIDI CD2022-02-11Officer16.8k
LAGANO ROXANNED2022-02-11Officer13.57k
DAVID GLENN CD2022-02-11Officer27.79k
TRAWICKI ROMAND2022-02-11Officer15.51k
NAYAK ABHAY UD2022-02-11Officer1.29k
POLZER ROBERT JD2022-02-11Officer1.94k
LAGANO ROXANNESale at price 241.70 per share.D2021-12-23Officer1.31k
PECK KRISTIN CSale at price 221.92 - 225.44 per share.D2021-11-26Chief Executive Officer14.5k
PECK KRISTIN CConversion of Exercise of derivative security at price 30.89 per share.D2021-11-26Chief Executive Officer12k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Zoetis Inc - Class A. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Zoetis Inc - Class A

Here is the result of two systematic investment strategies applied to Zoetis Inc - Class A. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Zoetis Inc - Class A

The following chart shows the equity curve of the two systematic investment strategies applied to Zoetis Inc - Class A:

Zoetis Inc - Class A automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 66.77% on the backtest period.

Performance at glance

Performance

66.77 %

Latent gain

1557.38 $

Invested capital

2332.49 $

Annualized return

16.13 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Zoetis Inc - Class A

This is the result of two momentum investment strategies applied to Zoetis Inc - Class A. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Zoetis Inc - Class A

The following chart shows all the entries opened by the momentum investment system on Zoetis Inc - Class A:

Zoetis Inc - Class A momentum entries
  • The first momentum investment strategy would give 95.68% of return on Zoetis Inc - Class A. That represents 5505.65$ of latent gain with 5754.5$ of employed capital.
  • The second momentum investment strategy would give 89.52% of return on Zoetis Inc - Class A. That represents 4061.53$ of latent gain with 4537.13$ of employed capital.
Performance at glance (1Q Momentum)

Performance

95.68 %

Latent gain

5505.65 $

Invested capital

5754.5 $

Annualized return

24.95 %
Performance at glance (2Q Momentum)

Performance

89.52 %

Latent gain

4061.53 $

Invested capital

4537.13 $

Annualized return

24.46 %

Momentum equity curve on Zoetis Inc - Class A

The following chart shows the equity curve of the two momentum strategies applied to Zoetis Inc - Class A:

Zoetis Inc - Class A momentum equity

Note: the dividends potentially given by Zoetis Inc - Class A are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Zoetis Inc - Class A

The following chart shows the employed capital evolution of the two momentum strategies on Zoetis Inc - Class A since the beginning:

Zoetis Inc - Class A

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Zoetis Inc - Class A

Buy the dip entry openings on Zoetis Inc - Class A

Zoetis Inc - Class A

The performance achieved by the robo-advisor on Zoetis Inc - Class A is 53.39%. That represents 570.08$ of latent gain with 1067.76$ of employed capital. The following chart shows Zoetis Inc - Class A stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Zoetis Inc - Class A, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

53.39 %

Latent gain

570.08 $

Invested capital

1067.76 $

Annualized return

24.95 %

Equity curve of the strategy applied to Zoetis Inc - Class A

The following chart shows the result of the investment strategy applied to Zoetis Inc - Class A:

Zoetis Inc - Class A

Note: the dividends potentially given by Zoetis Inc - Class A are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Zoetis Inc - Class A

The following chart shows the employed capital evolution since the beginning of the investment strategy on Zoetis Inc - Class A:

Zoetis Inc - Class A

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Zoetis Inc - Class A

In this section, I will compare the three previous investment strategies applied to Zoetis Inc - Class A.

Equity curve comparison on Zoetis Inc - Class A

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Zoetis Inc - Class A investment strategy comparison

Employed capital comparison on Zoetis Inc - Class A

Zoetis Inc - Class A investment comparison

Performance comparison on Zoetis Inc - Class A

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 66.77% 1557.38$ 2332.49$ 16.13%
Momentum 1 quarter 95.68% 5505.65$ 5754.5$ 24.53%
Momentum 2 quarters 89.52% 4061.53$ 4537.13$ 24.46%
Non-directional 53.39% 570.08$ 1067.76$ 24.95%
Annualized return comparison

Automatic investment

16.13 %

Momentum 1Q

24.46 %

Momentum 2Q

24.46 %

Non-directional

24.95 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Zoetis Inc - Class A:

Note: The algorithm computes the probability of correlation between Zoetis Inc - Class A and the other stocks. There may be false positives or some missing correlated stocks. If the price of Zoetis Inc - Class A does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Zoetis Inc - Class A
Country United States
City Parsippany
Address 10 Sylvan Way
Phone 973 822 7000
Website www.zoetis.com
FullTime employees 13800
Industry Drug Manufacturers—Specialty & Generic
Sector Healthcare
Exchange XNYS
Ticker ZTS
Market www.nyse.com

Zoetis Inc - Class A ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 1.4
Peer Environment Performance 2.0330864197531
Environment Percentile unknown
Palm Oil no
Nuclear no
Fur Leather no
GMO no
Coal no
Pesticides no
Animal Testing yes

Social scores

Social ESG Factors Scores
Social Score 8.1
Peer Social Performance 14.299012345679
Social Percentile unknown
Highest Controversy 1
Peer Highest Controversy Performance 1.8780487804878
Adult no
Gambling no
Alcoholic no
Tobacco no
Catholic no
Controversial Weapons no
Small Arms no
Military Contract no
Peer Count yes

Related Controversy: Employee IncidentsCustomer IncidentsSociety & Community Incidents


Governance scores

Governance ESG Factors Scores
Governance Score 8.9
Peer Governance Performance 8.8141975308642
Governance Percentile unknown

ESG at glance
Total ESG Scores: 18.5
Environment Score: 1.4
Social Score: 8.1
Governance Score: 8.9

ESG Performance: UNDER_PERF

Peer Group: Pharmaceuticals

Peer Esg Score Performance: 25.306097560976

Rating Year: 2022

Rating Month: 8

Max Age: 86400

Percentile: 20